Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,259,233 papers from all fields of science
Search
Sign In
Create Free Account
lurtotecan liposome
Known as:
liposomal lurtotecan
, liposome, lurtotecan
A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (2)
NX 211
OSI 211
lurtotecan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
G. Dark
,
A. Calvert
,
+15 authors
E. Eisenhauer
Journal of Clinical Oncology
2005
Corpus ID: 23300279
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan…
Expand
2005
2005
Phase I study of OSI-211 (liposomal lurtotecan) in combination with liposomal doxorubicin (LD) every 3 weeks in patients (pts) with advanced solid tumors; final analysis suggests benefit in…
D. Mendelson
,
M. Brewer
,
+6 authors
M. Gordon
2005
Corpus ID: 78128951
2074 Background: OSI-211 is a topoisomerase (topo) I inhibitor in liposomal formulation. In vivo efficacy of the liposomal…
Expand
2005
2005
Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC)
C. Poole
,
H. Thomas
,
+6 authors
M. Ptaszynski
2005
Corpus ID: 73932460
5017 Background: OSI-211 is a liposomal formulation of lurtotecan, a topoisomerase-I inhibitor. In a previous randomised dose…
Expand
2005
2005
P-789 Phase II study of OSI-211 (liposomal lurtotecan) in recurrentsmall-cell lung cancer (SCLC)
M. Ranson
,
T. Dobbs
,
+6 authors
M. Ptaszynski
2005
Corpus ID: 71675791
Highly Cited
2004
Highly Cited
2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
M. Seiden
,
F. Muggia
,
+6 authors
E. Barrett
Gynecologic Oncology
2004
Corpus ID: 46057643
2004
2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
F. Duffaud
,
M. Borner
,
+8 authors
P. Fumoleau
European Journal of Cancer
2004
Corpus ID: 22702207
2004
2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K. Gelmon
,
H. Hirte
,
+5 authors
E. Eisenhauer
Investigational new drugs
2004
Corpus ID: 6518825
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal…
Expand
2003
2003
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
B. Tomkinson
,
R. Bendele
,
+7 authors
D. Emerson
Leukemia research : a Forum for Studies on…
2003
Corpus ID: 5849112
2001
2001
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice
John P Desjardins
,
Elizabeth A Abbott
,
+8 authors
Frank C Richardson
Anti-Cancer Drugs
2001
Corpus ID: 40347972
Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. Lurtotecan…
Expand
1999
1999
Clinical pharmacokinetics of liposomal lurtotecan (NX211) in whole blood, plasma and urine.
D. Kehrer
,
A. Bos
,
+5 authors
J. Verweij
1999
Corpus ID: 89560600
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE